Skip to main content

Table 4 Oncological results

From: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study

 

Per-nodule

  

1 months

  

0.33

 Complete response

42.4% (81/191)

40.0% (14/35)

0.79

 Partial response

19.9% (38/191)

25.7% (9/35)

0.44

 Stable disease

34.6% (66/191)

25,7% (9/35)

0.31

 Progressive disease

3.1% (6/191)

8.6% (3/35)

0.13

 Objective response

62.3% (119/191)

65.7% (23/35)

0.70

 Disease control

96.8% (185/191)

91.4% (32/35)

0.13

3–6 months

  

0.14

 Complete response

45.6% (62/136)

44.8% (13/29)

0.94

 Partial response

11.8% (16/136)

27.6% (8/29)

0.03°

 Stable disease

30.1% (41/136)

20.7% (6/29)

0.31

 Progressive disease

12.5% (17/136)

6.9% (2/29)

0.39

 Objective response

57.4% (78/136)

72.4% (21/29)

0.13

 Disease control

87.5% (119/136)

93.1% (27/29)

0.39

9–12 months

  

0.03

 Complete response

50.6% (45/89)

68.4% (13/19)

0.24

 Partial response

3.4% (3/89)

10.5% (2/19)

0.18

 Stable disease

30.3% (27/89)

0% (0/19)

0.006

 Progressive disease

15.7% (14/89)

21.1% (4/19)

0.57

 Objective response

53.9% (48/89)

78.9% (15/19)

0.05

 Disease control

84.3% (75/89)

78.9% (15/19)

0.50

  1. CI: confidence interval; DEM-TAC: drug eluting embolics trans-arterial chemoembolization; B-TACE: balloon trans-arterial chemoembolization; LAF: last available follow-up. ° The Bonferroni’s correction in this case significantly addressed p at 0.0125 (0.05/4)